Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer

Jennifer R. Bellon, Karen L. Lindsley, Georgiana K. Ellis, Julie R. Gralow, Robert B Livingston, Mary M. Austin Seymour

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purpose: Evidence supports the inclusion of the taxanes in the treatment of breast cancer. A recent randomized trial has shown a survival advantage to the addition of paclitaxel in the adjuvant treatment of node-positive patients. Several studies have suggested diminished local control if adjuvant radiation is delayed, while in vitro and in vivo studies have demonstrated a benefit of concurrent administration of taxanes with radiation. For these reasons, we began in 1995 to administer radiation therapy concurrently with the taxanes in advanced breast cancer. This retrospective review examines the feasibility of such treatment. Methods and Materials: Forty-four patients were treated with concurrent radiation and either paclitaxel (29 patients) or docetaxel (15 patients). One patient received both paclitaxel and docetaxel. Eighteen patients were treated for recurrent disease, 9 had received prior radiation. Toxicity was assessed by the RTOG scale for acute and late effects. Results: Concurrent radiation and taxane chemotherapy was well tolerated. Nine patients (20%) experienced Grade 3 acute skin toxicity. This was more likely with docetaxel than paclitaxel (p = 0.04). Among patients undergoing breast conservation, there were no Grade 3 toxicities. With a median follow-up of 11 months, 1 patient has developed breast fibrosis. Conclusion: Concurrent administration of both paclitaxel and docetaxel with radiation resulted in acceptable toxicity. Overall, the acute skin toxicity seen with docetaxel was more pronounced. However, among patients undergoing breast conservation the taxanes were both well tolerated. Further study is necessary to assess the impact of concurrent treatment on long-term outcome. (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)393-397
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume48
Issue number2
DOIs
StatePublished - Sep 2000
Externally publishedYes

Fingerprint

docetaxel
chemotherapy
Paclitaxel
breast
radiation therapy
Radiotherapy
cancer
Breast Neoplasms
Drug Therapy
Taxoids
toxicity
Radiation
radiation
Breast
conservation
grade
fibrosis
Skin

Keywords

  • Breast
  • Docetaxel
  • Paclitaxel
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. / Bellon, Jennifer R.; Lindsley, Karen L.; Ellis, Georgiana K.; Gralow, Julie R.; Livingston, Robert B; Austin Seymour, Mary M.

In: International Journal of Radiation Oncology Biology Physics, Vol. 48, No. 2, 09.2000, p. 393-397.

Research output: Contribution to journalArticle

Bellon, Jennifer R. ; Lindsley, Karen L. ; Ellis, Georgiana K. ; Gralow, Julie R. ; Livingston, Robert B ; Austin Seymour, Mary M. / Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. In: International Journal of Radiation Oncology Biology Physics. 2000 ; Vol. 48, No. 2. pp. 393-397.
@article{78f69451505647a89772ff520ce3c3c0,
title = "Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer",
abstract = "Purpose: Evidence supports the inclusion of the taxanes in the treatment of breast cancer. A recent randomized trial has shown a survival advantage to the addition of paclitaxel in the adjuvant treatment of node-positive patients. Several studies have suggested diminished local control if adjuvant radiation is delayed, while in vitro and in vivo studies have demonstrated a benefit of concurrent administration of taxanes with radiation. For these reasons, we began in 1995 to administer radiation therapy concurrently with the taxanes in advanced breast cancer. This retrospective review examines the feasibility of such treatment. Methods and Materials: Forty-four patients were treated with concurrent radiation and either paclitaxel (29 patients) or docetaxel (15 patients). One patient received both paclitaxel and docetaxel. Eighteen patients were treated for recurrent disease, 9 had received prior radiation. Toxicity was assessed by the RTOG scale for acute and late effects. Results: Concurrent radiation and taxane chemotherapy was well tolerated. Nine patients (20{\%}) experienced Grade 3 acute skin toxicity. This was more likely with docetaxel than paclitaxel (p = 0.04). Among patients undergoing breast conservation, there were no Grade 3 toxicities. With a median follow-up of 11 months, 1 patient has developed breast fibrosis. Conclusion: Concurrent administration of both paclitaxel and docetaxel with radiation resulted in acceptable toxicity. Overall, the acute skin toxicity seen with docetaxel was more pronounced. However, among patients undergoing breast conservation the taxanes were both well tolerated. Further study is necessary to assess the impact of concurrent treatment on long-term outcome. (C) 2000 Elsevier Science Inc.",
keywords = "Breast, Docetaxel, Paclitaxel, Radiation",
author = "Bellon, {Jennifer R.} and Lindsley, {Karen L.} and Ellis, {Georgiana K.} and Gralow, {Julie R.} and Livingston, {Robert B} and {Austin Seymour}, {Mary M.}",
year = "2000",
month = "9",
doi = "10.1016/S0360-3016(00)00636-2",
language = "English (US)",
volume = "48",
pages = "393--397",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer

AU - Bellon, Jennifer R.

AU - Lindsley, Karen L.

AU - Ellis, Georgiana K.

AU - Gralow, Julie R.

AU - Livingston, Robert B

AU - Austin Seymour, Mary M.

PY - 2000/9

Y1 - 2000/9

N2 - Purpose: Evidence supports the inclusion of the taxanes in the treatment of breast cancer. A recent randomized trial has shown a survival advantage to the addition of paclitaxel in the adjuvant treatment of node-positive patients. Several studies have suggested diminished local control if adjuvant radiation is delayed, while in vitro and in vivo studies have demonstrated a benefit of concurrent administration of taxanes with radiation. For these reasons, we began in 1995 to administer radiation therapy concurrently with the taxanes in advanced breast cancer. This retrospective review examines the feasibility of such treatment. Methods and Materials: Forty-four patients were treated with concurrent radiation and either paclitaxel (29 patients) or docetaxel (15 patients). One patient received both paclitaxel and docetaxel. Eighteen patients were treated for recurrent disease, 9 had received prior radiation. Toxicity was assessed by the RTOG scale for acute and late effects. Results: Concurrent radiation and taxane chemotherapy was well tolerated. Nine patients (20%) experienced Grade 3 acute skin toxicity. This was more likely with docetaxel than paclitaxel (p = 0.04). Among patients undergoing breast conservation, there were no Grade 3 toxicities. With a median follow-up of 11 months, 1 patient has developed breast fibrosis. Conclusion: Concurrent administration of both paclitaxel and docetaxel with radiation resulted in acceptable toxicity. Overall, the acute skin toxicity seen with docetaxel was more pronounced. However, among patients undergoing breast conservation the taxanes were both well tolerated. Further study is necessary to assess the impact of concurrent treatment on long-term outcome. (C) 2000 Elsevier Science Inc.

AB - Purpose: Evidence supports the inclusion of the taxanes in the treatment of breast cancer. A recent randomized trial has shown a survival advantage to the addition of paclitaxel in the adjuvant treatment of node-positive patients. Several studies have suggested diminished local control if adjuvant radiation is delayed, while in vitro and in vivo studies have demonstrated a benefit of concurrent administration of taxanes with radiation. For these reasons, we began in 1995 to administer radiation therapy concurrently with the taxanes in advanced breast cancer. This retrospective review examines the feasibility of such treatment. Methods and Materials: Forty-four patients were treated with concurrent radiation and either paclitaxel (29 patients) or docetaxel (15 patients). One patient received both paclitaxel and docetaxel. Eighteen patients were treated for recurrent disease, 9 had received prior radiation. Toxicity was assessed by the RTOG scale for acute and late effects. Results: Concurrent radiation and taxane chemotherapy was well tolerated. Nine patients (20%) experienced Grade 3 acute skin toxicity. This was more likely with docetaxel than paclitaxel (p = 0.04). Among patients undergoing breast conservation, there were no Grade 3 toxicities. With a median follow-up of 11 months, 1 patient has developed breast fibrosis. Conclusion: Concurrent administration of both paclitaxel and docetaxel with radiation resulted in acceptable toxicity. Overall, the acute skin toxicity seen with docetaxel was more pronounced. However, among patients undergoing breast conservation the taxanes were both well tolerated. Further study is necessary to assess the impact of concurrent treatment on long-term outcome. (C) 2000 Elsevier Science Inc.

KW - Breast

KW - Docetaxel

KW - Paclitaxel

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=0033828059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033828059&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(00)00636-2

DO - 10.1016/S0360-3016(00)00636-2

M3 - Article

VL - 48

SP - 393

EP - 397

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -